We are live on ! Find out more
SLXNW

Silexion Therapeutics Warrant
SLXNW

22 hedge funds and large institutions have $128K invested in Silexion Therapeutics Warrant in 2025 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

18% more capital invested

Capital invested by funds: $108K → $128K (+$19.9K)

0% more funds holding

Funds holding: 22 → 22 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

1.67% less ownership

Funds ownership: 44.83% → 43.16% (-1.7%)

Holders
22
Holders Change
–
Holders Change %
0%
% of All Funds
0.29%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
1
Closed
1
Calls
$56K
Puts
–
Net Calls
+$56K
Net Calls Change
-$117K

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$2.42K
2
OMC
Oasis Management Company
Cayman Islands
+$390
3
Goldman Sachs
Goldman Sachs
New York
+$108

Top Sellers

Rank Fund Capital Flow
1
HP
Hartree Partners
New York
-$6.4K
2
CS
Clear Street
New York
-$7
Name Holding Trade Value Shares
Change 		Change in
Stake
OMC
1
Oasis Management Company
Cayman Islands
$37.8K +$390 +11,111 New
PAMP
2
Polar Asset Management Partners
Ontario, Canada
$26.2K – – –
LA
3
Linden Advisors
New York
$12.2K – – –
AC
4
Aristeia Capital
Connecticut
$8.34K – – –
Susquehanna International Group
5
Susquehanna International Group
Pennsylvania
$7.75K +$2.42K +69,071 +46%
CS
6
Clear Street
New York
$7.73K -$7 -200 -0.1%
SBLIC
7
Security Benefit Life Insurance Company
Kansas
$5.28K – – –
Goldman Sachs
8
Goldman Sachs
New York
$4.11K +$108 +3,071 +3%
KC
9
Kepos Capital
New York
$4K – – –
Jane Street
10
Jane Street
New York
$2.64K – – –
CCM
11
Context Capital Management
California
$1.8K – – –
TCM
12
Tenor Capital Management
New York
$1.76K – – –
GCIA
13
Gabelli & Co Investment Advisers
New York
$1.34K – – –
DCM
14
Dupont Capital Management
Delaware
$1.14K – – –
Neuberger Berman Group
15
Neuberger Berman Group
New York
$1.11K – – –
GF
16
Gabelli Funds
New York
$1.07K – – –
MTCM
17
Mint Tower Capital Management
Netherlands
$1K – – –
PMAM
18
Picton Mahoney Asset Management
Ontario, Canada
$1K – – –
Stifel Financial
19
Stifel Financial
Missouri
$563 – – –
SCM
20
Saba Capital Management
New York
$421 – – –
CCA
21
Cobblestone Capital Advisors
New York
$352 – – –
Bank of America
22
Bank of America
North Carolina
$4 – – –
HP
23
Hartree Partners
New York
– -$6.4K -182,355 Closed

SLXNW Hedge Fund Activity: Q3 2025 in Review

22 of the 7,626 institutional investors tracked by Wall St. Rank reported a position in Silexion Therapeutics Warrant (SLXNW) for Q3 2025, worth a combined $128K — up 18% from $108K a quarter earlier.

Fund positioning in SLXNW was balanced in Q3 2025: 1 fund opened new positions, 1 closed out, 2 added to existing stakes and 1 trimmed.

The largest buyer was Susquehanna International Group, adding an estimated $2.42K. The largest seller was Hartree Partners, exiting entirely with an estimated $6.4K sold.

  • 22 institutional investors held Silexion Therapeutics Warrant (SLXNW) as of Q3 2025, unchanged from Q2 2025.
  • Funds reported $128K of Silexion Therapeutics Warrant stock for Q3 2025, up 18% quarter-over-quarter.
  • 1 fund opened new Silexion Therapeutics Warrant positions in Q3 2025 and 1 closed out, a net change of 0 holders.
  • The largest Silexion Therapeutics Warrant buyer in Q3 2025 was Susquehanna International Group, an estimated $2.42K added.
  • The largest Silexion Therapeutics Warrant seller in Q3 2025 was Hartree Partners, an estimated $6.4K sold.

Based on aggregated 13F filings for Q3 2025.